Immunogenicity is an important concern for therapeutic antibodies during drug development. By analyzing co-crystal structures of idiotypic antibodies and their antibodies, we found that anti-idiotypic antibodies usually bind the Complementarity Determining Regions (CDR) of idiotypic antibodies. Sequence and structural features were identified for distinguishing immunogenic antibodies from non-immunogenic antibodies. For example, non-immunogenic antibodies have a significantly larger cavity volume at the CDR region and a more hydrophobic CDR-H3 loop than immunogenic antibodies. Antibodies containing no Gly at the turn of CDR-H2 loop are often immunogenic. We integrated these features together with a machine learning platform to Predict Immun...
Antibodies - key molecules of the immune system - are increasingly used as ther- apeutic drugs. The ...
Computational modelling of antibody structures plays a critical role in therapeutic antibody design....
One of the major obstacles in the successful clinical application of monoclonal antibodies has been ...
Antibodies are natural proteins that are central to the function of the immune system. With high aff...
Therapeutic antibodies are widely used for disease detection and specific treatments. However, as an...
MOTIVATION: The precise targeting of antibodies and other protein therapeutics is required for their...
Motivation: Monoclonal antibody therapeutics are often produced from non-human sources (typically mu...
Antibodies are an essential part of the immune system. They are able to attain high specificity and...
Antibodies are soluble proteins produced by the adaptive immune system to bind and counteract invadi...
One third of all drugs currently in development are monoclonal antibody therapeutics. Key to the eff...
Antibodies are important immunological molecules that can bind a diverse array of foreign molecules....
Antibodies are used extensively in medical and biological research. Their complementarity determinin...
One of the main challenges in modern molecular biology is to establish general, robust, and precise ...
Abstract Antibody humanization is a key step in the preclinical phase of the development of therapeu...
The optimization of therapeutic antibodies is time-intensive and resource-demanding, largely because...
Antibodies - key molecules of the immune system - are increasingly used as ther- apeutic drugs. The ...
Computational modelling of antibody structures plays a critical role in therapeutic antibody design....
One of the major obstacles in the successful clinical application of monoclonal antibodies has been ...
Antibodies are natural proteins that are central to the function of the immune system. With high aff...
Therapeutic antibodies are widely used for disease detection and specific treatments. However, as an...
MOTIVATION: The precise targeting of antibodies and other protein therapeutics is required for their...
Motivation: Monoclonal antibody therapeutics are often produced from non-human sources (typically mu...
Antibodies are an essential part of the immune system. They are able to attain high specificity and...
Antibodies are soluble proteins produced by the adaptive immune system to bind and counteract invadi...
One third of all drugs currently in development are monoclonal antibody therapeutics. Key to the eff...
Antibodies are important immunological molecules that can bind a diverse array of foreign molecules....
Antibodies are used extensively in medical and biological research. Their complementarity determinin...
One of the main challenges in modern molecular biology is to establish general, robust, and precise ...
Abstract Antibody humanization is a key step in the preclinical phase of the development of therapeu...
The optimization of therapeutic antibodies is time-intensive and resource-demanding, largely because...
Antibodies - key molecules of the immune system - are increasingly used as ther- apeutic drugs. The ...
Computational modelling of antibody structures plays a critical role in therapeutic antibody design....
One of the major obstacles in the successful clinical application of monoclonal antibodies has been ...